Ryan D Nipp1, Arati V Rao2. 1. Department of Medicine, Duke University Medical Center, Durham, North Carolina. 2. Department of Medicine, Duke University Medical Center, Durham, North Carolina. arati.rao@dm.duke.edu.
Abstract
Acute myeloid leukemia (AML) is an aggressive disease that predominantly affects elderly patients. Cytokines and chemokines are major players in the pathogenesis of AML. They regulate the disease course and play a deleterious role in the progression of AML. The geriatric population is particularly vulnerable to these mediators as these cytokines and chemokines are also implicated in the development of frailty, fatigue, and declining cognitive function. It is the combination of these adverse effects of cytokines and chemokines that affect performance status and, in turn, the poor prognosis in this age group. Cytokines and chemokines are emerging as therapeutic targets in AML. Future endeavors to treat AML will likely involve cytokines and chemokines as attempts are made to disrupt the bone marrow environment. By modulating the bone marrow stroma, the goal is to create an environment less favorable to AML cells and more favorable to the effects of chemotherapy against AML.
Acute myeloid leukemia (AML) is an aggressive disease that predominantly affects elderly patients. Cytokines and chemokines are major players in the pathogenesis of AML. They regulate the disease course and play a deleterious role in the progression of AML. The geriatric population is particularly vulnerable to these mediators as these cytokines and chemokines are also implicated in the development of frailty, fatigue, and declining cognitive function. It is the combination of these adverse effects of cytokines and chemokines that affect performance status and, in turn, the poor prognosis in this age group. Cytokines and chemokines are emerging as therapeutic targets in AML. Future endeavors to treat AML will likely involve cytokines and chemokines as attempts are made to disrupt the bone marrow environment. By modulating the bone marrow stroma, the goal is to create an environment less favorable to AML cells and more favorable to the effects of chemotherapy against AML.
Authors: Marc Buyse; Pierre Squifflet; Beverly J Lange; Todd A Alonzo; Richard A Larson; Jonathan E Kolitz; Stephen L George; Clara D Bloomfield; Sylvie Castaigne; Sylvie Chevret; Didier Blaise; Dominique Maraninchi; Kathryn J Lucchesi; Tomasz Burzykowski Journal: Blood Date: 2011-04-25 Impact factor: 22.113
Authors: Laura Barreyro; Britta Will; Boris Bartholdy; Li Zhou; Tihomira I Todorova; Robert F Stanley; Susana Ben-Neriah; Cristina Montagna; Samir Parekh; Andrea Pellagatti; Jacqueline Boultwood; Elisabeth Paietta; Rhett P Ketterling; Larry Cripe; Hugo F Fernandez; Peter L Greenberg; Martin S Tallman; Christian Steidl; Constantine S Mitsiades; Amit Verma; Ulrich Steidl Journal: Blood Date: 2012-06-21 Impact factor: 22.113
Authors: Elihu H Estey; Peter F Thall; Francis J Giles; Xue-Mei Wang; Jorge E Cortes; Miloslav Beran; Sherry A Pierce; Deborah A Thomas; Hagop M Kantarjian Journal: Blood Date: 2002-06-15 Impact factor: 22.113
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Bruno Nervi; Pablo Ramirez; Michael P Rettig; Geoffrey L Uy; Matthew S Holt; Julie K Ritchey; Julie L Prior; David Piwnica-Worms; Gary Bridger; Timothy J Ley; John F DiPersio Journal: Blood Date: 2008-12-02 Impact factor: 22.113
Authors: Shabbir M H Alibhai; Marc Leach; Vikas Gupta; George A Tomlinson; Joseph M Brandwein; Fernando Suarez Saiz; Mark D Minden Journal: Crit Rev Oncol Hematol Date: 2008-09-07 Impact factor: 6.312